ReportWire

Tag: Inflation Reduction Act

  • Senior citizens will pay a lot more for Medicare in 2026

    [ad_1]

    (CNN) — Senior citizens are the latest group of Americans to face steep increases in their health insurance premiums for 2026.

    Medicare Part B premiums will jump nearly 10% next year, the largest increase in four years and second-largest hike, in dollar terms, in the program’s history. The standard monthly premium will be $202.90, an increase of $17.90 from this year, according to the Centers for Medicare and Medicaid Services. That will eat up nearly one-third of the $56 monthly Social Security cost-of-living adjustment that retirees will receive in 2026.

    The steep increase in premiums for Medicare Part B — which covers doctors’ visits, outpatient hospital services, medical equipment and drugs administered by physicians, among other services — comes at a time when health insurance premiums are rising sharply for those with job-based coverage and Affordable Care Act policies. This upward trend puts more pressure on Americans already struggling with affordability as the prices of foodutilities and other necessities remain stubbornly high.

    “In a world in which people are concerned about the affordability of health care and all other needs, it’s pretty distressing that this increase is so large,” said Jeanne Lambrew, director of health care reform at The Century Foundation.

    Increasing medical and pharmaceutical costs, as well as usage, are common drivers of the rise in health care premiums across coverage types.

    Medicare is also contending with the continuing wave of baby boomers becoming eligible to enroll, plus the ongoing shift toward surgeries and other medical services being performed at outpatient facilities, rather than in hospitals, where care is covered by Medicare Part A, said Rachel Schmidt, research professor at Georgetown University’s Medicare Policy Initiative.

    CMS noted that monthly premiums would have risen by another $11 had it not approved a change in payment for skin substitutes that the agency says will reduce spending by nearly 90% on the wound care products. Medicare shelled out more than $10 billion for these products last year, up from $256 million in 2019.

    Meanwhile, Medicare Part D prescription drug policies, which are offered by insurers, will see fewer changes for 2026 than they did for this year. The Biden administration had to rush last fall to stand up a multibillion-dollar subsidy program for insurers to prevent steep premium increases stemming from the Inflation Reduction Act. The law, which the Democrat-led Congress approved in 2022, required insurers to be on the hook for more of the drug costs once enrollees hit the catastrophic coverage phase above a $2,000 cap.

    The number of plans being offered for 2026 will decrease modestly, according to consulting firm Oliver Wyman, which noted that Elevance is exiting the market. Many insurers are hiking their premiums by as much as $50 for next year, though some are lowering them or holding them steady.

    “If seniors in the standalone PDP market are willing to shop, there is still stability,” said Brooks Conway, a principal at Oliver Wyman.

    Roughly 69 million Americans are enrolled in Medicare, which also covers people with disabilities. The annual open enrollment period ends December 7.

    Medicare Advantage market retrenches

    Medicare Advantage, which covers just over half of Medicare beneficiaries, is going through a second year of major changes. The overhaul is being spurred by medical costs outpacing reimbursements from the federal government, which pays insurers to offer coverage to Medicare enrollees.

    Many enrollees will have to search for new coverage for 2026 since the number of offerings is tumbling 10% to 3,373 plans, according to Oliver Wyman. Major insurers, including CVS Aetna, Elevance, Humana and UnitedHealthcare, are reducing their plan options in at least 100 counties. The changes are expected to affect just over 2 million people.

    (These figures do not include special needs plans that cater to enrollees with chronic conditions or those who are dually eligible for Medicaid. These plans will have more offerings for 2026 than they did this year.)

    In certain counties, there will be fewer policies offered with $0 premiums and fewer PPO plans, which have wider provider networks, said Greg Berger, a partner at Oliver Wyman. Insurers are primarily seeking to exit or scale back their less profitable products and geographic areas.

    “A lot of MAPD plans are trying not to grow,” Berger said, referring to Medicare Advantage plans with prescription drug coverage.

    And for the first time, some Americans will have no Medicare Advantage plans to choose from. Blue Cross and Blue Shield of Vermont and UnitedHealthcare decided to discontinue their coverage in the Green Mountain State, leaving traditional Medicare as the only option for residents in eight counties.

    Yet even with the pullbacks, most Medicare beneficiaries will have an array of options in 2026 — 39 plans, on average, down from 42 plans this year.

    “Millions of Medicare beneficiaries will continue to have access to a broad range of affordable coverage options in 2026,” Dr. Mehmet Oz, CMS’ administrator, said in a statement.

    Also, fewer plans will offer $0 deductibles for prescription drugs, while maximum out-of-pocket limits for medical care are rising $490, or about 10%, on average. Among Medicare Advantage plans with drug coverage that have a monthly premium, the average premium will increase to $66 next year, up from $60 this year.

    What’s more, the supplemental benefits that Medicare Advantage offers enrollees, such as funds for over-the-counter medicines, dental care and vision services, are getting skimpier. The dental allowance, for instance, is declining 10% to $2,107, on average, Berger said.

    The current disruptions in the market, however, don’t mean that Medicare Advantage will continue to shrink. Over the longer term, the program is still an attractive market for insurers, Schmidt said.

    “It’s not going away any time soon,” she said.

    [ad_2]

    Tami Luhby and CNN

    Source link

  • AGs sue Trump EPA over solar energy program

    [ad_1]

    BOSTON — Attorney General Andrea Campbell has joined about two dozen other Democrats in suing the Trump administration over its decision to pull the plug on a $7 billion solar energy program for low-income households.

    The lawsuit, filed in U.S. District Court in Washington, alleges that the U.S. Environmental Protection Agency violated federal law and the Administrative Procedures Act when it terminated the Solar for All program, approved by Congress in 2023 as part of the Biden administration’s Inflation Reduction Act.


    This page requires Javascript.

    Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

    kAm%96 pvD 2C8F6 E96 >@G6 H2D 8@G6C?>6?E “@G6CC6249” 2?5 E92E E96 t!p =24@?6J AC6G:@FD=J 2AAC@G65 3J r@?8C6DD 7@C E96 D@=2C AC@8C2>]k^Am

    kAm“!=2:?E:77D 92G6 366? 2?5 H:== 4@?E:?F6 E@ 36 92C>65 3J 5676?52?ED’ 6I64FE:G6 @G6CC6249[” E96 pvD HC@E6 😕 E96 C646?E=J 7:=65 bhA286 =2HDF:E] “qJ 2C3:EC2C:=J E6C>:?2E:?8 2 AC@8C2> 😕 H9:49 A=2:?E:77D A2CE:4:A2E65 2?5 H9:49 H2D 6IA64E65 E@ 3C:?8 DF3DE2?E:2= 36?67:ED E@ A=2:?E:77D 2?5 E96:C C6D:56?ED[ 5676?52?ED 92G6 :==682==J 6=:>:?2E65 A=2:?E:77D’ 23:=:EJ E@ A2CE:4:A2E6 😕 2?5 36?67:E 7C@> E96 $up !C@8C2>]”k^Am

    kAm%96 pvD 2=D@ 7:=65 2 D6A2C2E6 =2HDF:E %9FCD52J 😕 E96 &]$] r@FCE @7 u656C2= r=2:>D E@ C64@G6C 52>286D 7@C t!p’D “F?=2H7F= 3C6249 @7 E96 8C2?E 28C66>6?ED” F?56C E96 D@=2C AC@8C2>]k^Am

    kAm%H@ H666?E2= 8C@FAD[ D@=2C 4@>A2?:6D 2?5 =23@C F?:@?D 7:=65 2 D:>:=2C =2HDF:E 😕 &]$] s:DEC:4E r@FCE 😕 #9@56 xD=2?5[ H9:49 2=D@ D662?6?E :?;F?4E:@? 3=@4<:?8 E96 %CF>A 25>:?:DEC2E:@?’D >@G6]k^Am

    kAmx? pF8FDE[ t!p p5>:?:DEC2E@C {66 +6=5:? 2??@F?465 E96 AC@8C2>’D 42?46==2E:@?[ 42==:?8 :E 2 “3@@?5@88=6” E92E’D “C:76 H:E9 8C:7E” 7C@> F?D4CFAF=@FD 4@>A2?:6D E2<:?8 4FED 7C@> E96 7656C2==J 7F?565 8C2?ED]k^Am

    kAm|2DD249FD6EED H2D 2H2C565 S`de >:==:@? 7C@> E96 8C2?E AC@8C2>[ H9:49 DE2E6 @77:4:2=D D2J H@F=5 92G6 96=A65 4C62E6 8@@5A2J:?8 ;@3D[ =@H6C 6?6C8J 3:==D 7@C E6?D @7 E9@FD2?5D @7 =@H:?4@>6 4@?DF>6CD 2?5 255 2? 255:E:@?2= `ad >682H2EED @7 D@=2C A@H6C E@ E96 DE2E6’D 4=62?6?6C8J >:I]k^Am

    kAmr2>A36== D2:5 E96 %CF>A 25>:?:DEC2E:@?’D 2EE6>AE E@ “:==682==J 8FE” E96 AC@8C2> H:== “6=:>:?2E6 8@@5A2J:?8 ;@3D[ ?68=64E E96 52?86CD @7 4=:>2E6 492?86[ 2?5 C2:D6 4@DED 7@C =@H:?4@>6 C6D:56?ED]”k^Am

    kAm“pD |2DD249FD6EED 4@?E:?F6D E96 4C:E:42= EC2?D:E:@? E@ 4=62? 6?6C8J[ E96 $@=2C 7@C p== AC@8C2> 6?DFC6D E92E ?@ 4@>>F?:EJ 😀 =67E 369:?5 2?5 E92E 6G6CJ C6D:56?E 92D E96 @AA@CEF?:EJ E@ 36?67:E 7C@> 4=62?6C 2:C 2?5 >@C6 277@C523=6 FE:=:EJ 3:==D[” E96 s6>@4C2E D2:5 😕 2 DE2E6>6?E]k^Am

    kAm&?56C E96 AC@8C2>[ E96 DE2E6 :DDF65 8C2?ED E@ =6?5:?8 :?DE:EFE:@?D E92E 7F?5 D@=2C 2?5 32EE6CJ AC@;64ED[ 2D H6== 2D E@ :?DE2==6CD 2?5 AC@;64E 56G6=@A6CD H9@ 5@ E96 H@C<]k^Am

    kAm%96 q:56? 25>:?:DEC2E:@? 6DE:>2E65 E96 AC@8C2> H@F=5 AC@5F46 >@C6 E92? Sbd_ >:==:@? 😕 2??F2= D2G:?8D @? 6=64EC:4 3:==D 7@C =@H:?4@>6 9@FD69@=5D 24C@DD E96 4@F?ECJ[ H9:=6 4FEE:?8 8C66?9@FD6 82D 6>:DD:@?D 3J @G6C b_ >:==:@? >6EC:4 E@?D @7 42C3@? 5:@I:56 6BF:G2=6?E[ 6BF2= E@ E96 6>:DD:@?D @7 @G6C f >:==:@? EJA:42= A2DD6?86C G69:4=6D]k^Am

    kAm%CF>A AC@>:D65 E@ 6?5 E96 7656C2= 8@G6C?>6?E’D DFAA@CE 7@C H:?5[ D@=2C 2?5 @E96C C6?6H23=6 6?6C8J D@FC46D E92E 96 4=2:>D 2C6 E@@ 4@DE=J 7@C 4@?DF>6CD]k^Am

    kAms6DA:E6 E96 AFD9324< 7C@> E96 7656C2= 8@G6C?>6?E[ s6>@4C2E:4 v@G] |2FC2 w62=6J 2?5 E@A 6?G:C@?>6?E2= @77:4:2=D 2C6 G@H:?8 E@ AC6DD @? H:E9 677@CED E@ 5:G6CD:7J E96 DE2E6’D 6?6C8J >:I H:E9 >@C6 D@=2C A@H6C FD:?8 E96 DE2E6’D ?6E >6E6C:?8 AC@8C2> 2?5 @E96C :?:E:2E:G6D]k^Am

    kAm~? %9FCD52J[ w62=6J 2?5 DE2E6 6?G:C@?>6?E2= @77:4:2=D C@==65 @FE 2? FA52E65 D@=2C :?46?E:G6 AC@8C2> – $@=2C |2DD249FD6EED #6?6H23=6 %2C86E b]_ – E96J 4=2:>65 H:== 3C:?8 >@C6 =@H4@DE 6?6C8J :?E@ E96 DE2E6 2?5 C65F46 6=64EC:4:EJ 4@DED 3J Sb__ >:==:@?]k^Am

    kAm“%@ 5C:G6 5@H? 4@DED[ H6 ?665 >@C6 – 2?5 D@=2C 😀 E96 72DE6DE[ 4962A6DE 6?6C8J H6 42? 3C:?8 :?E@ |2DD249FD6EED[” w62=6J D2:5 😕 2 DE2E6>6?E] “|2DD249FD6EED 😀 @A6? 7@C D@=2C 3FD:?6DD]”k^Am

    kAmr9C:DE:2? |] (256 4@G6CD E96 |2DD249FD6EED $E2E69@FD6 7@C }@CE9 @7 q@DE@? |65:2 vC@FAUCDBF@jD ?6HDA2A6CD 2?5 H63D:E6D] t>2:= 9:> 2E k2 9C67lQ>2:=E@i4H256o4?9:?6HD]4@>Qm4H256o4?9:?6HD]4@>k^2m]k^Am

    Christian M. Wade covers the Massachusetts Statehouse for North of Boston Media Group’s newspapers and websites. Email him at cwade@cnhinews.com.

    [ad_2]

    By Christian M. Wade | Statehouse Reporter

    Source link

  • State unveils grant programs to rope in fed funding

    [ad_1]

    BOSTON — Cities and towns will have access to a new pool of state money to rope in federal infrastructure funds for fixing crumbling roads and bridges and redeveloping downtowns.

    A pair of new grant programs rolled out this week by the Healey administration will provide funding and technical assistance for local governments to go after federal infrastructure dollars, with nearly $5 million in competitive and formula funding available over the next two fiscal years.


    This page requires Javascript.

    Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

    kAm“|@C6 E649?:42= 2DD:DE2?46 >62?D C6G:E2=:K65 5@H?E@H?D[ D276C C@25D[ ?6H 9@>6D 2?5 >@C6 ;@3D 😕 @FC 4@>>F?:E:6D[” v@G] |2FC2 w62=6J D2:5 😕 2 DE2E6>6?E] “%96D6 ?6H E@@=D H:== AC@G:56 4C:E:42= DFAA@CE E@ @FC =@42= 8@G6C?>6?E =6256CD 2?5 H:== 36 2? :>A@CE2?E A2CE @7 @FC 4@?E:?F65 H@C< E@ >2<6 |2DD249FD6EED E96 36DE A=246 E@ =:G6[ H@C< 2?5 5@ 3FD:?6DD]”k^Am

    kAm%96 ?6H |F?:4:A2= 2?5 %C:32= pDD:DE2?46 vC2?E !C@8C2> H:== 36 2G2:=23=6 E@ =@42= 8@G6C?>6?ED 2?5 7656C2==JC64@8?:K65 EC:36D E@ D66< 8C2?ED 7@C :?7C2DECF4EFC6[ 4=:>2E6 2?5 64@?@>:4 56G6=@A>6?E AC@;64ED] p3@FE Sa]d >:==:@? H:== 36 2G2:=23=6 @G6C E96 ?6IE EH@ 7:D42= J62CD[ 244@C5:?8 E@ E96 w62=6J 25>:?:DEC2E:@?]k^Am

    kAm%96 >@?6J 42? 36 FD65 7@C 8C2?E HC:E:?8[ AC@;64E D4@A:?8[ 7:D42= 2?2=JD:D 2?5 A=2??:?8 2?5 762D:3:=:EJ DEF5:6D[ 2>@?8 @E96C FD6D]k^Am

    kAm%96 %649?:42= pDD:DE2?46 vC2?ED 7@C #68:@?2= !=2??:?8 p86?4:6D AC@8C2> 😀 7@C>F=232D65 8C2?E AC@8C2> 7@C C68:@?2= A=2??:?8 286?4:6D E@ AC@G:56 5:C64E E649?:42= 2DD:DE2?46 E@ 4:E:6D 2?5 E@H?D[ A2CE:4F=2C=J 7@C :?7C2DECF4EFC6[ 4=:>2E6[ 2?5 64@?@>:4 56G6=@A>6?E AC@;64ED] p3@FE Sa >:==:@? H:== 36 2G2:=23=6 @G6C E96 ?6IE EH@ J62CD[ @77:4:2=D D2:5]k^Am

    kAm%96 8C2?E AC@8C2>D H6C6 2FE9@C:K65 F?56C 2 7656C2= 7F?5:?8 3:== D:8?65 3J w62=6J =2DE $6AE6>36C E92E 5:G6CED :?E6C6DE 7C@> E96 DE2E6’D C6D6CG6 7F?5D E@ 4C62E6 2 “A2J2DJ@F8@” 42A:E2= 7F?5 E@ AFCDF6 2 >F49 =2C86C A@@= @7 7656C2= 7F?5D 7@C :?7C2DECF4EFC6 AC@;64ED]k^Am

    kAmw62=6J @77:4:2=D D2J E96 D@42==65 C2:?J 52J 7F?5[ H9:49 😀 2AAC@249:?8 Sh 3:==:@?[ 86?6C2E6D 2? 6DE:>2E65 Sad_ >:==:@? 😕 :?E6C6DE 2 J62C]k^Am

    kAm%96 =2H C6BF:C6D E96 DE2E6 r@>AEC@==6C E@ EC2?D76C :?E6C6DE 7C@> DE2E6 C6D6CG6D E@ E96 r@>>@?H62=E9 u656C2= |2E49:?8 2?5 s63E #65F4E:@? uF?5 H96? 2>@F?ED 6I4665 `_T @7 3F586E65 C6G6?F6D @7 E96 AC6G:@FD 7:D42= J62C[ AC@G:565 E92E E96 32=2?46 @7 E96 7F?5 92D?’E 564C62D65 😕 E96 AC6G:@FD J62C]k^Am

    kAmq24<6CD @7 E96 A=2? D2:5 :E H:== AF>A FA E@ Sg__ >:==:@? :?E@ E96 42A:E2= 7F?5 @G6C E96 ?6IE E9C66 J62CD]k^Am

    kAmw62=6J’D 7656C2= :?7C2DECF4EFC6 4K2C[ “F6?E:? !2=7C6J[ 92D A@:?E65 E@ >@C6 E92? S`f]d 3:==:@? 2G2:=23=6 7C@> 7656C2= 8C2?E AC@8C2>D[ H9:49 96 D2JD AC@G:56D 2? “F?AC64656?E65 @AA@CEF?:EJ” E@ E2A :?E@ 7656C2= 7F?5D E@ 255C6DD D@>6 @7 E96 DE2E6’D >@DE AC6DD:?8 :?7C2DECF4EFC6 ?665D]k^Am

    kAm%96 >@?6J H@F=5 4@>6 7C@> E96 x?7C2DECF4EFC6 x?G6DE>6?E 2?5 y@3D p4E[ 2 S`]aEC:==:@? DA6?5:?8 3:== D:8?65 3J E96? !C6D:56?E y@6 q:56? 😕 a_a`] u656C2= :?7C2DECF4EFC6 >@?6J 😀 2=D@ 2G2:=23=6 E9C@F89 E96 rwx!$ 2?5 $4:6?46 p4E 2?5 E96 x?7=2E:@? #65F4E:@? p4E]k^Am

    kAm~G6C2==[ |2DD249FD6EED DE2?5D E@ 86E Sh]b 3:==:@? 7C@> E96 :?7C2DECF4EFC6 =2H @G6C E96 ?6IE 7:G6 J62CD[ :?4=F5:?8 2E =62DE Sc]a 3:==:@? 7@C C@25H2J FA8C256D 2?5 S`]` 3:==:@? 7@C 3C:586 C6A2:CD]k^Am

    kAmqFE E96 DE2E6 😀 2=D@ 492D:?8 27E6C >@C6 E92? S`f]d 3:==:@? 😕 4@>A6E:E:G6 8C2?ED >256 2G2:=23=6 E9C@F89 E96 :?7C2DECF4EFC6 =2H 7@C =@42= 8@G6C?>6?ED E@ 7:I A@E9@=6D 2?5 4CF>3=:?8 3C:586D[ FA8C256 H2E6C 2?5 D6H6C DJDE6>D 2?5 @E96C ?665D]k^Am

    kAmv2C5?6C |2J@C |:4926= }:49@=D@?[ H9@ 9625D E96 |2DD249FD6EED |2J@CD pDD@4:2E:@?[ D2:5 ?2G:82E:?8 2AA=:42E:@?D 7@C 7656C2= AC@8C2>D “42? @7E6? 36 4@>A=6I 2?5 E:>64@?DF>:?8[ 6DA64:2==J 7@C D>2==6C @C F?56CD6CG65 4@>>F?:E:6D]”k^Am

    kAmw6 D2:5 E96 ?6H 8C2?ED 8:G6 4:E:6D 2?5 E@H?D “E96 E@@=D E96J ?665 E@ 2446DD C6D@FC46D[ >@G6 AC@;64ED 7@CH2C5[ 2?5 DEC6?8E96? =@42= :?7C2DECF4EFC6]”k^Am

    kAm“%9:D 😀 23@FE 3F:=5:?8 2 DEC@?86C r@>>@?H62=E9 7C@> E96 DEC66E =6G6= FA—96=A:?8 4@>>F?:E:6D @7 6G6CJ D:K6 F?=@4< @AA@CEF?:E:6D E92E H:== >2<6 |2DD249FD6EED D276C[ 962=E9:6C[ 2?5 >@C6 C6D:=:6?E 7@C E96 7FEFC6[” }:49@=D@? D2:5 😕 2 DE2E6>6?E]k^Am

    kAmr9C:DE:2? |] (256 4@G6CD E96 |2DD249FD6EED $E2E69@FD6 7@C }@CE9 @7 q@DE@? |65:2 vC@FAUCDBF@jD ?6HDA2A6CD 2?5 H63D:E6D] t>2:= 9:> 2E k2 9C67lQ>2:=E@i4H256o4?9:?6HD]4@>Qm4H256o4?9:?6HD]4@>k^2m]k^Am

    kAmr9C:DE:2? |] (256 4@G6CD E96 |2DD249FD6EED $E2E69@FD6 7@C }@CE9 @7 q@DE@? |65:2 vC@FAUCDBF@jD ?6HDA2A6CD 2?5 H63D:E6D] t>2:= 9:> 2E k2 9C67lQ>2:=E@i4H256o4?9:?6HD]4@>Qm4H256o4?9:?6HD]4@>k^2m]k^Am

    Christian M. Wade covers the Massachusetts Statehouse for North of Boston Media Group’s newspapers and websites. Email him at cwade@cnhinews.com.

    [ad_2]

    By Christian M. Wade Statehouse Reporter

    Source link

  • Batabyal: Drug pricing lessons for the us from global policies | Long Island Business News

    [ad_1]

    In Brief:

    There is bipartisan consensus that drugs in the U.S. cost a lot more than in other high-income countries; therefore, it is important to comprehend how governmental interventions in other nations can inform U.S. policy. Recent research on this topic has shed valuable light on the unique market conditions of drugs, including information asymmetries, insurance-mediated demand, and the role of patents in incentivizing innovation.

    To intervene constructively in drug markets, it is important to recognize that such markets deviate from perfectly competitive markets due to four salient factors. First, drugs are “credence goods” which means that their quality and efficacy are difficult for consumers to assess, necessitating regulatory oversight by, for instance, the U.S. Food and Drug Administration or the European Medicines Agency to ensure safety and efficacy. Second, there are high development costs. Developing new drugs is expensive but imitation is relatively easy once a drug is approved. In addition, patents and exclusive rights protect innovators but they can also limit free entry into the market.

    Third, consider the issue of insurance and moral hazard. The availability of insurance reduces price sensitivity among patients, thereby leading to higher consumption and enabling manufacturers to set higher prices, especially when they hold market power due to patents. Finally, one must account for the role played by the drug prescribing physicians who often display little sensitivity to the cost of drugs.

    Governments in other nations have used several approaches to regulate drug prices and thereby address the issues created by the above factors. First, there is cost-based pricing. This means that some countries such as the U.K.’s pharmaceutical price regulation scheme use “cost-plus” regulations which seek to tie drug prices to development costs. However, this approach risks rewarding inefficiency and lacks a link to the therapeutic value of drugs.

    Second, there is . This approach ties prices to a drug’s therapeutic benefits. While theoretically appealing, the approach requires robust technology assessments to measure the clinical value of drugs. These assessments may be inconsistently applied across nations.

    Third, we have cost-effectiveness thresholds that are used in the U.K. and Germany. These thresholds evaluate drugs by their cost per quality-adjusted life year (QALY). Drugs are reimbursed only if they meet a defined threshold. This approach limits moral hazard and provides clearer signals for investment but depends heavily on accurate data and value-of-life assumptions.

    Fourth, there is reference pricing. In internal reference pricing, the idea is to set reimbursement levels based on the prices of similar drugs within the same country, thereby encouraging competition but potentially limiting innovation. In contrast, in external reference pricing, drug prices are based on prices in other nations. While this approach promotes fairness, the approach can lead to delays in launching new drugs in low-price countries to prevent triggering lower prices in higher-revenue markets. Finally, parallel trade allows the reimportation of drugs from low-price markets, but this can reduce access in those markets and disrupt global pricing strategies.

    What does the use of these five approaches in other nations mean for the U.S.? The simple point is that the U.S. faces unique challenges in adopting these approaches. Why? For starters, consider the decentralized system in the U.S. Unlike countries with single-payer systems, the U.S. relies on private insurers and pharmacy benefit managers (PBMs) to negotiate prices, but this reliance prioritizes profits over social welfare.

    Next there is the issue of Medicare drug price negotiation: The Inflation Reduction Act of 2022 introduced Medicare price negotiations. Although the objective here is to reduce costs, the policy could produce unintended consequences, such as delayed product launches or reduced generic competition. Moreover, given the global weight of the U.S. market—accounting for a significant share of pharmaceutical revenues—any change in U.S. pricing policy could shift global innovation incentives.

    Owing to these problems, the research under discussion focuses on innovative solutions to balance the issues of drug access and drug innovation. A key solution is what is referred to as advance market commitments. The idea here is that payers commit to purchasing a drug, meeting specified criteria before development, as seen in Operation Warp Speed for COVID-19 vaccines. This reduces hold-up risk but requires precise criteria and international coordination.

    A second possible solution is what is known as subscription pricing. Payers pay a fixed fee for unlimited drug access, and there are pay-for-performance contracts, where drug reimbursement depends on real-world treatment outcomes. This kind of approach offers budget predictability and better alignment of price with value, but it requires sophisticated monitoring and faces implementation hurdles.

    Despite high drug prices, it is worth noting that pharmaceuticals are not the primary driver of overall healthcare cost growth in the U.S. Other factors such as high salaries for healthcare professionals contribute significantly. Therefore, we need to comprehend that while regulatory interventions can address market inefficiencies, policymakers must carefully balance static benefits (lower prices) with dynamic benefits (continued innovation).

    While other countries offer valuable lessons, the U.S. must tailor policies to its unique market structure and global responsibilities. Effective solutions should prioritize aligning prices with therapeutic value, reducing information asymmetries, and fostering innovation while ensuring access. The challenge lies in designing policies that achieve these goals without unintended consequences, such as reduced investment in critical therapies.

    Amit Batabyal is a distinguished professor, the Arthur J. Gosnell professor of economics, and the head of the Sustainability Department, all at the Rochester Institute of Technology but these views are his own.


    [ad_2]

    Opinion

    Source link

  • Judges side with Trump EPA over canceled Inflation Reduction Act grants to nonprofits | TechCrunch

    [ad_1]

    The battle over $20 billion worth of climate-related funding authorized by Congress continues as an appellate court ruled on Tuesday in favor of the Environmental Protection Agency, which had terminated Biden-era grants made to nonprofits.

    The legal tussle stems from EPA administrator Lee Zeldin’s decision to cancel grants dispersed as part of the Inflation Reduction Act. Zeldin said that the grants did not match the EPA’s current priorities and claimed, without evidence, that he had concerns about fraud.

    A district court had previously ruled that Zeldin’s actions were “arbitrary and capricious.”

    The two majority justices, both Trump appointees, wrote that Zeldin’s cancellation of the contracts was valid and that the government “must ensure proper oversight and management” of the grants. They cited in support of their decision an undercover video taken by Project Veritas, a conservative activist group that releases deceptively edited videos.

    In March, court filings revealed that the EPA along with the FBI and the EPA inspector general had instructed Citibank to freeze money that had already been placed in accounts controlled by the nonprofits. The money was largely to be used for loans, which would be paid back and reused.

    The grants in question were awarded to a range of nonprofits, including Climate United and Power Forward. At the time of the March hearing, Climate United had committed to $392 million in projects based on the money in its accounts, including $63 million for solar power developments in Oregon and Idaho and another $31.8 million in solar projects in rural Arkansas. Power Forward had committed $539 million and said the freeze left it unable to pay contractors’ outstanding invoices.

    Zeldin had claimed that fraud was one of his main concerns, though a lengthy investigation by the interim U.S. attorney in Washington, D.C., failed to turn up any meaningful evidence, according to a report in The New York Times.

    Techcrunch event

    San Francisco
    |
    October 27-29, 2025

    Perhaps as a result of a lack of evidence of fraud, EPA arguments before the appeals court focused on the contractual nature of the grants. The majority of justices agreed that the matter should be heard by the U.S. Court of Federal Claims, not the broader federal judiciary.

    The dissenting justice, an Obama appointee, said that the EPA “has no lawful basis — nor even a nonfrivolous assertion of any basis — to interfere with funding that, pursuant to Congress’s instructions, already belongs to Plaintiffs.”

    The plaintiffs are likely to appeal to the U.S. Supreme Court. If they fail there, the EPA could still be liable for billions of dollars, according to legal analysis by its own attorneys.

    [ad_2]

    Tim De Chant

    Source link

  • Lawmakers approve plan to rope in federal funding

    Lawmakers approve plan to rope in federal funding

    [ad_1]

    BOSTON — Massachusetts wants to rope in billions of dollars in federal infrastructure funds to fix crumbling roads and bridges and transition to clean energy, but the state needs to pony up some of its own money to get it.

    That will happen under a proposal, approved by the state Legislature on Thursday, that calls for leveraging state funds to go after billions of dollars in competitive federal grants that will be made available through President Joe Biden’s jobs and infrastructure law and other programs.

    The plan, filed last year by Gov. Maura Healey, will divert interest from the state’s reserve funds to create a “pay-as-you-go” capital fund to pursue a much larger pool of federal funds for infrastructure projects.

    Healey officials say the so-called rainy day fund, which is approaching $9 billion, generates an estimated $250 million in interest a year.

    “Remaining competitive, equitable, and affordable as a commonwealth means thinking creatively about our state’s finances and seizing opportunities,” Senate President Karen Spilka, D-Ashland, said in a prepared statement.

    “We have been fiscally prudent in building up the largest rainy day fund in Massachusetts’ history, which allows us to leverage our robust interest earnings to compete for federal dollars that will help us strengthen our infrastructure,” she said.

    If Healey signs the bill, as expected, it will require the state Comptroller to transfer interest from state reserves to the Commonwealth Federal Matching and Debt Reduction Fund when amounts exceed 10% of budgeted revenues of the previous fiscal year, provided that the balance of the fund hasn’t decreased in the previous year.

    Backers of the plan said it will pump up to $800 million into the capital fund over the next three years.

    Healey’s federal infrastructure czar, Quentin Palfrey, has pointed to more than $17.5 billion available from federal grant programs which he says provides an “unprecedented opportunity” to tap into federal funds to address some of the state’s most pressing infrastructure needs.

    The money would come from the Infrastructure Investment and Jobs Act, a $1.2-trillion spending bill signed by Biden in 2021. Federal infrastructure money is also available through the CHIPS and Science Act and the Inflation Reduction Act.

    Overall, Massachusetts stands to get $9.3 billion from the infrastructure law over the next five years, including at least $4.2 billion for roadway upgrades and $1.1 billion for bridge repairs, according to the Biden administration.

    At least $1.1 billion will be directed to improving water and sewer infrastructure and address outfalls that spew sewage into the Merrimack River, while at least $100 million will provide broadband internet coverage to rural communities.

    The state will also get $2.5 billion for upgrades on its public transit system. Other funding would be devoted to airport upgrades and incentives for drivers to switch to electric vehicles.

    It’s also slated to get $147 million to help expand high-speed broadband internet service to underserved regions of the state.

    But the state is also chasing after more than $17.5 billion in competitive grants made available through the infrastructure law for local governments to fix potholes and crumbling bridges, upgrade water and sewer systems and other needs.

    Healey officials say they will need to ante up at least $3 billion in state matching funds to be competitive in that process. The state has already earmarked $2 billion, they say.

    Money from the federal laws is already flowing into the state, including $108 million from the U.S. Department of Transportation to improve rail service in western and central Massachusetts.

    The state is also getting $1 billion in federal funding from the infrastructure law to help cover the cost of replacing two Cape Cod bridges.

    Republicans have expressed concerns about the Democratic governor controlling billions of dollars in federal funding and have sought to put guardrails on use of the money.

    Data provided by the Biden administration shows only about 25% of Massachusetts’ 5,229 bridges are in good condition. About 9% are considered structurally deficient.

    Besides structurally deficient bridges, many of the state’s roadways are in major disrepair, according to the White House.

    The Biden administration’s Infrastructure Report Card gave the state a grade of C-, saying there are at least 1,194 miles of highway in poor condition.

    Christian M. Wade covers the Massachusetts Statehouse for North of Boston Media Group’s newspapers and websites. Email him at cwade@cnhinews.com.

    [ad_2]

    By Christian M. Wade | Statehouse Reporter

    Source link

  • IRS collected $1 billion in back taxes from millionaires in less than a year

    IRS collected $1 billion in back taxes from millionaires in less than a year

    [ad_1]

    Washington (CNN) — The Internal Revenue Service said Thursday that it has collected more than $1 billion in past-due taxes from millionaires since last fall – thanks to a ramp up of enforcement efforts funded by the Democrat-backed Inflation Reduction Act that passed Congress nearly two years ago.

    The Biden administration is eager to show how the IRS is using the money to crack down on wealthy tax cheats and improve taxpayers services. Republicans, who have criticized the funding as wasteful spending, have made several efforts to chip away at the 10-year investment provided by the legislation.

    Last fall, the IRS launched an initiative to collect from wealthy individuals who have not paid the taxes they owe. The agency identified about 1,600 taxpayers with more than $1 million in income and more than $250,000 in tax debt. To date, more than $1 billion has been recovered from those individuals, and the effort is ongoing.

    Prior to the Inflation Reduction Act, the IRS did not have the staffing or resources to pursue high-income earners that the agency knew owed taxes, IRS Commissioner Danny Werfel said on a call with reporters.

    “The taxes were clearly owed by these people, but we didn’t have the people or the resources to follow up with them,” Werfel said.

    The process of collecting past-due taxes starts with a letter to the taxpayer’s home. They are given a certain amount of time to either pay the back taxes or dispute the matter. The rest of the process varies depending on the taxpayer’s situation.

    Targeting wealthy tax cheats

    The IRS has launched a series of initiatives over the past two years to crack down on wealthy tax cheats.

    For example, it is ramping up audits of wealthy taxpayers, corporations and large business partnerships by hiring more staff and using artificial intelligence. The agency is also examining the personal use of corporate jets.

    Some of the funding from the Inflation Reduction Act is being used to modernize taxpayer services. As a result, the agency was able to answer 1 million more calls this year than it did during the previous tax season. Efforts to digitize the agency’s 1 billion pieces of paper are also underway.

    Earlier this year, the IRS launched a pilot version of its own tax filing service that allowed Americans to file their returns for free directly with the IRS. More than 140,000 people used the program, known as Direct File, to successfully file their tax returns and the IRS plans to expand the program next year.

    Battles over IRS funding

    The Inflation Reduction Act, which passed without any Republican votes, approved about $80 billion for the IRS over a 10-year period.

    But Republicans have made several efforts to claw back the money. In a deal to address the debt ceiling and avoid a US default last year, Democrats agreed to allow for $20 billion of the Inflation Reduction Act funds to be rescinded.

    In January, Democrats conceded an acceleration of the $20 billion cut in an effort to get a full-year federal spending law passed in time to avoid a partial government shutdown.

    [ad_2]

    Katie Lobosco and CNN

    Source link

  • Albany man sentenced for stealing federal funds

    Albany man sentenced for stealing federal funds

    [ad_1]

    ALBANY, N.Y. (NEWS10) — An Albany man will spend 18 months in jail for stealing federal funds meant for farmers. The U.S. Attorney’s Office said Asjid Parvez, 38, stole nearly $1 million in funds from the Inflation Reduction Act.

    Officials said the funds were stolen back in 2022, but he did not admit to stealing the funds until last year. The Inflation Reduction Act was designed to financially help people who fell behind of replaying federal farm loans.

    The FBI said it has already recovered more than half a million dollars of the stolen money.

    [ad_2]

    Courtney Ward

    Source link

  • Biden gives Americans a financial incentive to not buy a tesla

    Biden gives Americans a financial incentive to not buy a tesla

    [ad_1]

    Starting in 2024, the U.S. government will enforce updated Federal Tax Credit guidelines for electric vehicles (EVs), a move that has sparked backlash and speculation about the Biden administration’s motives, as the change affects one of the most popular models from the best-selling EV maker in the U.S.

    Under the revised provisions of the Inflation Reduction Act, the eligibility criteria for the coveted $7,500 point-of-sale tax credit will tighten, effectively sidelining popular models like Tesla‘s Model 3 Rear Wheel Drive and the Model 3 Long Range. Amid a flurry of tweets, Tesla enthusiasts are questioning whether the changes are part of a broader strategy to curb Tesla’s market dominance in the EV market, which currently stands at 53.79 percent.

    Tesla leads the electric vehicle market in the U.S., commanding over half of total EV sales, as illustrated in this breakdown by brand. The graph highlights the contrast between Tesla’s market share and that of its closest competitors.

    The U.S. Department of the Treasury and the Internal Revenue Service, earlier this month, released new guidelines aimed at invigorating domestic manufacturing and fortifying supply chains against foreign entities of concern which include Russia, North Korea, China, and Iran. According to Secretary Janet L. Yellen, the Inflation Reduction Act heralds a new era of American manufacturing prowess, with nearly $100 billion in clean vehicle investments since its enactment.

    Yet, starting on January 1, 2024, clean vehicles with battery components or critical minerals linked to foreign entities of concern like China will no longer be eligible for the full tax credit.

    The bar graph illustrates Tesla’s sales performance per quarter, showing the dominance of the Model 3 and Model Y, which significantly outpace the sales of Models S and X.

    Tesla’s Model 3 Rear Wheel Drive and the Model 3 Long Range will no longer qualify for the tax credit in 2024 due to their reliance on certain Chinese-made batteries. Tesla’s website acknowledged the shift, urging customers to complete purchases by the end of 2023 to benefit from the full tax credit.

    Newsweek has reached out to the White House and Tesla via email for comment.

    The reaction on social media was swift, with prominent Tesla investor Sawyer Merritt highlighting the abrupt end to the Model 3’s tax credit eligibility on the X platform, formerly known as Twitter. “Tesla has received updated guidance from the IRS. The Model 3 RWD & Long Range will lose the ENTIRE $7,500 Federal EV credit starting January 1, 2024.” The investor continued, “Tesla previously thought the EV credit for those trims would be cut to $3,750, but now their interpretation is $0. Take delivery by Dec 31 for full tax credit.”

    Subsequent tweets have ignited a debate, with accusations of the Biden administration’s bias against Tesla and Elon Musk. “So what you’re saying is… when the legacy auto manufacturers for whom these credits were meant to benefit all scale back their EV ambitions, the administration changed the rules to make sure Tesla loses the benefit,” one X user said. “Seems like a vendetta against Elon,” another replied.

    Another user highlighted the perceived lack of support for Tesla, saying, “America’s most domestically-based manufacturer receives zero help from the government.”

    The relationship between President Biden and Elon Musk has been nothing short of turbulent, users on X say. Despite a recent moment of accord earlier this year concerning Tesla’s commitment to expanding its charging network, there has been a history of mutual jabs and overt omissions from EV summits which point to a dynamic between the President and the richest man in the world.

    The impending revisions to the EV tax credit system have implications for Tesla’s market share and consumer choices, rendering the affected Tesla models effectively $7,500 more expensive on January 1, 2024, compared to their price on December 31, 2023.

    In an aerial view, the exterior of the Tesla automotive company manufacturing facility is seen. The updated regulations issued by the U.S. Department of the Treasury regarding the $7,500 Federal Tax Credit removes multiple Tesla Model 3 builds, creating public backlash.
    Justin Sullivan/Getty Images